Global Benign Prostatic Hyperplasia Treatment Market Report 2025

Benign Prostatic Hyperplasia Treatment Global Market Report 2025 - By Treatment (Minimal Invasive Surgery, Invasive Surgery), By Therapeutic Class (Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes), By End User (Home Healthcare, Hospitals And Clinics, Research And Manufacturing) - Market Size, Trends, And Global Forecast 2025-2034

Benign Prostatic Hyperplasia Treatment Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : March 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Benign Prostatic Hyperplasia Treatment Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

What Is Covered Under Benign Prostatic Hyperplasia Treatment Market

Benign prostatic hyperplasia (BPH) treatment refers to medical, minimally invasive, and surgical approaches used to manage the symptoms of an enlarged prostate. BPH is a common condition in aging men, leading to urinary issues such as frequent urination, weak stream, and incomplete bladder emptying.

The main treatments of benign prostatic hyperplasia (BPH) include minimally invasive surgery (MIS) and invasive surgery. Minimally Invasive Surgery (MIS) refers to surgical techniques that use small incisions, specialized instruments, and advanced imaging technology to perform procedures with minimal trauma to the body. The therapeutic classes for BPH treatment include alpha blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other therapeutic classes. These treatments cater to various end users, including Home Healthcare, hospitals and clinics, as well as research and manufacturing facilities.

How Is The Benign Prostatic Hyperplasia Treatment Market Segmented?

The benign prostatic hyperplasia treatment market covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery, Invasive Surgery

2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes

3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy

Benign Prostatic Hyperplasia Treatment Market Size and growth rate 2025 to 2029: Graph

What Is The Benign Prostatic Hyperplasia Treatment Market Size 2025 And Growth Rate?

The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing awareness and screening initiatives, rising prevalence of BPH, increasing healthcare awareness, improving healthcare infrastructure, and growing elderly population.

What Is The Benign Prostatic Hyperplasia Treatment Market Growth Forecast?

The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, a growing number of geriatric patients, a rising availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Major trends in the forecast period include developing targeted therapies, integration of digital health solutions, innovation in surgical options, integration of 3D imaging for diagnosis, and innovation in patient-centered care models.

What Is Driving The Benign Prostatic Hyperplasia Treatment Market: Rising Adoption Of Minimally Invasive Surgeries Driving Growth In BPH Treatment

The rise in adoption of minimally invasive surgeries is expected to propel the growth of the benign prostatic hyperplasia treatment market going forward. Minimally invasive surgeries are procedures that involve small incisions or no incisions at all, using specialized instruments to reduce recovery time, pain, and risk of complications. The rise in adoption of minimally invasive surgeries is driven by benefits such as shorter recovery times, reduced pain, lower risk of complications, and improved cosmetic outcomes. Benign prostatic hyperplasia treatment through minimally invasive surgeries provides patients with reduced recovery times, lower risks of complications, and effective symptom relief, enhancing overall surgical outcomes. For instance, in September 2023, according to the American Society of Plastic Surgeons (ASPS), a US-based professional association, in 2022, a total of 23,672,269 cosmetic minimally invasive procedures were performed globally, including treatments such as neuromodulator injections, lip augmentation, and non-invasive skin tightening. Therefore, the rise in adoption of minimally invasive surgeries is driving the growth of the benign prostatic hyperplasia treatment market.

Who Are The Major Players In The Global Benign Prostatic Hyperplasia Treatment Market?

Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.

What Are The Key Trends Of The Global Benign Prostatic Hyperplasia Treatment Market: Innovative Approaches In Benign Prostatic Hyperplasia Treatment Minimally Invasive Techniques For Enhanced Recovery

Major companies operating in the benign prostatic hyperplasia treatment market are prioritizing the development of innovative solutions, including minimally invasive procedures, to enhance patient outcomes and shorten recovery times. These procedures involve small or no incisions, minimizing trauma, pain, and complications while offering a faster recovery compared to traditional surgical methods. For instance, in December 2022, Teleflex Incorporated, a US-based medical device company, launched the UroLift System to treat benign prostatic hyperplasia. This system utilizes small permanent implants to reposition enlarged prostate tissue, offering significant symptom relief without the need for tissue removal, cutting, or heating. This outpatient treatment ensures rapid recovery, preserves sexual function, and delivers superior symptom relief compared to traditional BPH medications, with side effects typically resolving within two to four weeks.

What Are Latest Mergers And Acquisitions In The Benign Prostatic Hyperplasia Treatment Market: Laborie Medical Technologies Acquires Urotronic To Expand Interventional Urology Portfolio

In October 2023, Laborie Medical Technologies, Inc., a US-based medical technology company, acquired Urotronic for $600 million. With this acquisition, Laborie Medical Technologies aims to expand its interventional urology portfolio, enhance its technological capabilities, and strengthen its global market position in minimally invasive urological treatments. Urotronic, Inc. is a US-based medical device company that specifically develops and markets a minimally invasive treatment for benign prostatic hyperplasia (BPH).

What Is The Regional Outlook For The Global Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the benign prostatic hyperplasia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Benign Prostatic Hyperplasia Treatment  Market?

The benign prostatic hyperplasia treatment market consists of revenues earned by entities by providing services such as pharmacological treatments, minimally invasive procedures, surgical treatments, diagnostic services, and prostatic stents. The market value includes the value of related goods sold by the service provider or included within the service offering. The benign prostatic hyperplasia treatment market also includes sales of transurethral microwave thermotherapy, prostatic urethral lift, acupuncture, combination therapy, phosphodiesterase-5 inhibitors, and minimally invasive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Benign Prostatic Hyperplasia Treatment  Industry?

The benign prostatic hyperplasia treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia treatment market statistics, including the benign prostatic hyperplasia treatment industry's global market size, regional shares, competitors with a benign prostatic hyperplasia treatment market share, detailed benign prostatic hyperplasia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Benign Prostatic Hyperplasia Treatment Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $8.71 billion
Revenue Forecast In 2034 $10.83 billion
Growth Rate CAGR of 5.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Benign Prostatic Hyperplasia Treatment Market Characteristics

    3. Benign Prostatic Hyperplasia Treatment Market Trends And Strategies

    4. Benign Prostatic Hyperplasia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Benign Prostatic Hyperplasia Treatment Growth Analysis And Strategic Analysis Framework

    5.1. Global Benign Prostatic Hyperplasia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Benign Prostatic Hyperplasia Treatment Market Growth Rate Analysis

    5.4. Global Benign Prostatic Hyperplasia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Benign Prostatic Hyperplasia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Benign Prostatic Hyperplasia Treatment Total Addressable Market (TAM)

    6. Benign Prostatic Hyperplasia Treatment Market Segmentation

    6.1. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Minimal Invasive Surgery

    Invasive Surgery

    6.2. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Alpha Blockers

    5-Alpha Reductase Inhibitors

    Phosphodiesterase-5 Inhibitors

    Other Therapeutic classes

    6.3. Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Home Healthcare

    Hospitals And Clinics

    Research And Manufacturing

    6.4. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Minimal Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Transurethral Resection of the Prostate (TURP)

    Laser Surgery

    Prostatic Urethral Lift

    Transurethral Incision of the Prostate (TUIP)

    Microwave Therapy

    6.5. Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Open Prostatectomy

    Robotic Prostatectomy

    7. Benign Prostatic Hyperplasia Treatment Market Regional And Country Analysis

    7.1. Global Benign Prostatic Hyperplasia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Benign Prostatic Hyperplasia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market

    8.1. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Benign Prostatic Hyperplasia Treatment Market

    9.1. China Benign Prostatic Hyperplasia Treatment Market Overview

    9.2. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Benign Prostatic Hyperplasia Treatment Market

    10.1. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Benign Prostatic Hyperplasia Treatment Market

    11.1. Japan Benign Prostatic Hyperplasia Treatment Market Overview

    11.2. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Benign Prostatic Hyperplasia Treatment Market

    12.1. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Benign Prostatic Hyperplasia Treatment Market

    13.1. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Benign Prostatic Hyperplasia Treatment Market

    14.1. South Korea Benign Prostatic Hyperplasia Treatment Market Overview

    14.2. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Benign Prostatic Hyperplasia Treatment Market

    15.1. Western Europe Benign Prostatic Hyperplasia Treatment Market Overview

    15.2. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Benign Prostatic Hyperplasia Treatment Market

    16.1. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Benign Prostatic Hyperplasia Treatment Market

    17.1. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Benign Prostatic Hyperplasia Treatment Market

    18.1. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Benign Prostatic Hyperplasia Treatment Market

    19.1. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Benign Prostatic Hyperplasia Treatment Market

    20.1. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Benign Prostatic Hyperplasia Treatment Market

    21.1. Eastern Europe Benign Prostatic Hyperplasia Treatment Market Overview

    21.2. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Benign Prostatic Hyperplasia Treatment Market

    22.1. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Benign Prostatic Hyperplasia Treatment Market

    23.1. North America Benign Prostatic Hyperplasia Treatment Market Overview

    23.2. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Benign Prostatic Hyperplasia Treatment Market

    24.1. USA Benign Prostatic Hyperplasia Treatment Market Overview

    24.2. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Benign Prostatic Hyperplasia Treatment Market

    25.1. Canada Benign Prostatic Hyperplasia Treatment Market Overview

    25.2. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Benign Prostatic Hyperplasia Treatment Market

    26.1. South America Benign Prostatic Hyperplasia Treatment Market Overview

    26.2. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Benign Prostatic Hyperplasia Treatment Market

    27.1. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Benign Prostatic Hyperplasia Treatment Market

    28.1. Middle East Benign Prostatic Hyperplasia Treatment Market Overview

    28.2. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Benign Prostatic Hyperplasia Treatment Market

    29.1. Africa Benign Prostatic Hyperplasia Treatment Market Overview

    29.2. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape And Company Profiles

    30.1. Benign Prostatic Hyperplasia Treatment Market Competitive Landscape

    30.2. Benign Prostatic Hyperplasia Treatment Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Merck And Co Inc Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    31. Benign Prostatic Hyperplasia Treatment Market Other Major And Innovative Companies

    31.1. GlaxoSmithKline Public Limited Company

    31.2. Medtronic Public Limited Company

    31.3. Mezzion Pharma Co Ltd

    31.4. Eli Lilly and Company

    31.5. Teva Pharmaceutical Industries Ltd.

    31.6. Boehringer Ingelheim

    31.7. Boston Scientific Corporation

    31.8. Astellas Pharma Inc.

    31.9. Olympus Corporation

    31.10. Coloplast Group

    31.11. Teleflex Incorporated

    31.12. Cook Medical Incorporated

    31.13. AngioDynamics, Inc.

    31.14. HistoSonics Inc

    31.15. Urovant Sciences Ltd

    32. Global Benign Prostatic Hyperplasia Treatment Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Benign Prostatic Hyperplasia Treatment Market

    34. Recent Developments In The Benign Prostatic Hyperplasia Treatment Market

    35. Benign Prostatic Hyperplasia Treatment Market High Potential Countries, Segments and Strategies

    35.1 Benign Prostatic Hyperplasia Treatment Market In 2029 - Countries Offering Most New Opportunities

    35.2 Benign Prostatic Hyperplasia Treatment Market In 2029 - Segments Offering Most New Opportunities

    35.3 Benign Prostatic Hyperplasia Treatment Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Minimal Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Benign Prostatic Hyperplasia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Benign Prostatic Hyperplasia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Pfizer Inc. Financial Performance
  • Table 77: Merck And Co Inc Financial Performance
  • Table 78: AbbVie Inc. Financial Performance
  • Table 79: Bayer AG Financial Performance
  • Table 80: Sanofi S.A. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Minimal Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Benign Prostatic Hyperplasia Treatment Market, Sub-Segmentation Of Invasive Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Benign Prostatic Hyperplasia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Benign Prostatic Hyperplasia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Benign Prostatic Hyperplasia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Pfizer Inc. Financial Performance
  • Figure 77: Merck And Co Inc Financial Performance
  • Figure 78: AbbVie Inc. Financial Performance
  • Figure 79: Bayer AG Financial Performance
  • Figure 80: Sanofi S.A. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Benign Prostatic Hyperplasia Treatment market?

Benign prostatic hyperplasia (BPH) treatment refers to medical, minimally invasive, and surgical approaches used to manage the symptoms of an enlarged prostate. BPH is a common condition in aging men, leading to urinary issues such as frequent urination, weak stream, and incomplete bladder emptying. For further insights on the Benign Prostatic Hyperplasia Treatment market, request a sample here

How will the Benign Prostatic Hyperplasia Treatment market drivers and restraints affect the market dynamics? What forces will shape the Benign Prostatic Hyperplasia Treatment industry going forward?

The Benign Prostatic Hyperplasia Treatment market major growth driver - Rising Adoption Of Minimally Invasive Surgeries Driving Growth In BPH Treatment. For further insights on the Benign Prostatic Hyperplasia Treatment market, request a sample here

What is the forecast market size or the forecast market value of the Benign Prostatic Hyperplasia Treatment market?

The Benign Prostatic Hyperplasia Treatment market size has grown strongly in recent years. The benign prostatic hyperplasia treatment market size has grown strongly in recent years. It will grow from $8.23 billion in 2024 to $8.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to growing awareness and screening initiatives, rising prevalence of BPH, increasing healthcare awareness, improving healthcare infrastructure, and growing elderly population. The benign prostatic hyperplasia treatment market size is expected to see strong growth in the next few years. It will grow to $10.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the rising adoption of minimally invasive procedures, a growing number of geriatric patients, a rising availability of advanced treatment options, a growing focus on patient-centric care, and a rising prevalence of comorbidities. Major trends in the forecast period include developing targeted therapies, integration of digital health solutions, innovation in surgical options, integration of 3D imaging for diagnosis, and innovation in patient-centered care models. For further insights on the Benign Prostatic Hyperplasia Treatment market, request a sample here

How is the Benign Prostatic Hyperplasia Treatment market segmented?

The benign prostatic hyperplasia treatment market covered in this report is segmented –
1) By Treatment: Minimal Invasive Surgery, Invasive Surgery
2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes
3) By End User: Home Healthcare, Hospitals And Clinics, Research And Manufacturing

Subsegments:
1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy
2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy For further insights on the Benign Prostatic Hyperplasia Treatment market,
request a sample here

Which region has the largest share of the Benign Prostatic Hyperplasia Treatment market? What are the other regions covered in the report?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Benign Prostatic Hyperplasia Treatment market, request a sample here.

Who are the major players in the Benign Prostatic Hyperplasia Treatment market?

Major companies operating in the benign prostatic hyperplasia treatment market are Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd. . For further insights on the Benign Prostatic Hyperplasia Treatment market, request a sample here.

What are the key trends in the Benign Prostatic Hyperplasia Treatment market?

Major trends in the Benign Prostatic Hyperplasia Treatment market include Innovative Approaches In Benign Prostatic Hyperplasia Treatment Minimally Invasive Techniques For Enhanced Recovery. For further insights on the Benign Prostatic Hyperplasia Treatme request a sample here.

What are the major opportunities in the Benign Prostatic Hyperplasia Treatment market? What are the strategies for the Benign Prostatic Hyperplasia Treatment market?

For detailed insights on the major opportunities and strategies in the Benign Prostatic Hyperplasia Treatment market, request a sample here.

How does the Benign Prostatic Hyperplasia Treatment market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Benign Prostatic Hyperplasia Treatment market growth and SWOT analysis of the Benign Prostatic Hyperplasia Treatment industry, request a sample here.

For detailed insights on Benign Prostatic Hyperplasia Treatment's relation to the overall economy and other similar markets,

What are the latest mergers and acquisitions in the Benign Prostatic Hyperplasia Treatment industry? request a sample here.

For detailed insights on the mergers and acquisitions in the Benign Prostatic Hyperplasia Treatment industry,

What are the key dynamics influencing the Benign Prostatic Hyperplasia Treatment market growth? SWOT analysis of the Benign Prostatic Hyperplasia Treatment market. request a sample here.